邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

AJCC第8版乳腺癌预后分期重大更新及临床意义

周斌,  辛灵,  程元甲,  刘倩,  徐玲,  叶京明,  段学宁,  刘荫华

downloadPDF
文章导航 > 协和医学杂志  > 2017 >  8(4-5): 235-238
周斌, 辛灵, 程元甲, 刘倩, 徐玲, 叶京明, 段学宁, 刘荫华. AJCC第8版乳腺癌预后分期重大更新及临床意义[J]. 协和医学杂志, 2017, 8(4-5): 235-238. doi: 10.3969/j.issn.1674-9081.2017.05.008
引用本文: 周斌, 辛灵, 程元甲, 刘倩, 徐玲, 叶京明, 段学宁, 刘荫华. AJCC第8版乳腺癌预后分期重大更新及临床意义[J]. 协和医学杂志, 2017, 8(4-5): 235-238. doi: 10.3969/j.issn.1674-9081.2017.05.008
shu
Bin ZHOU, Ling XIN, Yuan-jia CHENG, Qian LIU, Ling XU, Jing-ming YE, Xue-ning DUAN, Yin-hua LIU. Critical Updates and Clinical Significance of the 8th Edition of AJCC Breast Cancer Prognostic Staging System[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 235-238. doi: 10.3969/j.issn.1674-9081.2017.05.008
Citation: Bin ZHOU, Ling XIN, Yuan-jia CHENG, Qian LIU, Ling XU, Jing-ming YE, Xue-ning DUAN, Yin-hua LIU. Critical Updates and Clinical Significance of the 8th Edition of AJCC Breast Cancer Prognostic Staging System[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 235-238. doi: 10.3969/j.issn.1674-9081.2017.05.008
shu

AJCC第8版乳腺癌预后分期重大更新及临床意义

doi: 10.3969/j.issn.1674-9081.2017.05.008

  • 北京大学第一医院乳腺疾病中心, 北京 100034

基金项目: 

首都医学发展科研基金资助项目 2009-1011

首都临床特色应用研究资助项目 Z131107002213007

国家重点研发计划精准医学研究重点专项项目 2016YFC0901300

详细信息
    通讯作者:

    刘荫华  电话:010-83575053,E-mail:liuyinhua@medmail.com.cn

  • 中图分类号: R737.9

Critical Updates and Clinical Significance of the 8th Edition of AJCC Breast Cancer Prognostic Staging System

  • Breast Disease Center, Peking University First Hospital, Beijing 100034, China

More Information

    摘要
  • 摘要: 随着肿瘤相关研究的深入以及基因检测技术在临床应用水平的进步, 肿瘤综合诊治理念已经在细化解剖学分期、精确掌握宏观肿瘤负荷的基础上跨越至分析肿瘤生物学特性、研发靶向治疗药物的新阶段。美国癌症联合会(American Joint Committee on Cancer, AJCC)第8版乳腺癌分期系统专家委员会依据雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)、人类表皮生长因子受体-2(human epidermal growth factor receptor-2, HER-2)及组织学分级4项生物标志物及多基因检测信息, 首次建立了全新的乳腺癌预后分期评价系统。其优先采用预后分期系统进行评价的临床推荐原则, 将成为人类与癌症抗争史上重大的革命性事件。癌症分期体系从宏观解剖学到微观病理学, 并逐渐加入多基因检测信息, 标志着肿瘤治疗从群体治疗到分类治疗的进步, 并推动乳腺癌诊治进入个体化时代。
    Abstract: The in-depth study of tumors and the evolution of gene detection techniques in the level of clinical application have promoted the comprehensive treatment of tumors from the age of refining anatomic staging, and precisely evaluating anatomic tumor burden, to the age of analyzing the biological feature, and developing target medicine. The panel of the American Joint Committee on Cancer(AJCC), for the first time, in the 8th edition of breast cancer staging system, built the prognostic staging system based on estrogen receptor(ER), progesterone receptor(PR), human epidermal growth factor receptor-2(HER-2), histologic grade(G), and multi-gene expression panels. The principle that the prognostic staging system is more recommended will be a revo-lution in the history of the war between human and cancer. The evolution of cancer staging system from anatomic level to micropathologic and multigenetic level shows that the cancer treatment has stepped into classification-based treatment from population-based treatment. This evolution will promote the arrival of personalized treatment.
    • HTML全文
    • 参考文献(21)
  • [1] Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017. doi:10.3322/caac.21393.[Epub ahead of print]
    [2] Singletary SE, Connolly JL. Breast cancer staging:working with the sixth edition of the AJCC Cancer Staging Manual[J]. CA Cancer J Clin, 2006, 56:37-47. doi:  10.3322/canjclin.56.1.37
    [3] 周斌, 季科, 辛灵, 等.美国肿瘤联合会乳腺癌分期系统(第8版)更新内容介绍及解读[J].中国实用外科杂志, 2017, (1):10-14. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsywkzz201701004
    [4] Amin MB, Edge S, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York:Springer, 2016:589-628.
    [5] Mcguire WL. Hormone receptors:their role in predicting prognosis and response to endocrine therapy[J]. Semin Oncol, 1978, 5:428-433. http://europepmc.org/abstract/MED/734443
    [6] Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis:a prospective cohort of breast cancer patients[J]. Breast Cancer Res, 2007, 9:R6. doi:  10.1186/bcr1639
    [7] Purdie CA, Quinlan P, Jordan LB, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer:a population-based study[J]. Br J Cancer, 2014, 110:565-572. doi:  10.1038/bjc.2013.756
    [8] Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer:ten years of targeted anti-HER-2 therapy and personalized medicine[J]. Oncologist, 2009, 14:320-368. doi:  10.1634/theoncologist.2008-0230
    [9] Yarden Y. Biology of HER2 and its importance in breast cancer[J]. Oncology, 2001, 61:1-13. http://www.ncbi.nlm.nih.gov/pubmed/11694782
    [10] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. J Clin Oncol, 2007, 25:118-145. http://cn.bing.com/academic/profile?id=d6e2a4e0ba49fdc1c2c8878676f5fe6d&encoded=0&v=paper_preview&mkt=zh-cn
    [11] Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31:3997-4013. doi:  10.1200/JCO.2013.50.9984
    [12] Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years[J]. Br J Cancer, 1957, 11:359-377. doi:  10.1038/bjc.1957.43
    [13] Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up[J]. Histopathology, 1991, 19:403-410. doi:  10.1111/j.1365-2559.1991.tb00229.x
    [14] Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005[J]. Ann Oncol, 2005, 16:1569-1583. doi:  10.1093/annonc/mdi326
    [15] Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer 2007[J]. Ann Oncol, 2007, 18:1133-1144. doi:  10.1093/annonc/mdm271
    [16] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 2011, 22:1736-1747. doi:  10.1093/annonc/mdr304
    [17] Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24:2206-2223. doi:  10.1093/annonc/mdt303
    [18] Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer:St Gallen international expert consensus on the primary therapy of early breast cancer 2015[J]. Ann Oncol, 2015, 26:1533-1546. doi:  10.1093/annonc/mdv221
    [19] 叶青, 江泽飞.三阴性乳腺癌精准治疗的机遇[J].中国肿瘤临床, 2016, (24):1074-1077. doi:  10.3969/j.issn.1000-8179.2016.24.048
    [20] Matsen CB, Neumayer LA. Breast cancer:a review for the general surgeon[J]. JAMA Surg, 2013, 148:971-979. doi:  10.1001/jamasurg.2013.3393
    [21] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual:continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin, 2017, 67:93-99. doi:  10.3322/caac.21388
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  63
  • HTML全文浏览量:  45
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-05-12
  • 刊出日期:  2017-09-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！